On Wednesday 29 March, trading started in Biovica’s shares at Nasdaq First North in Stockholm.

Biovica International AB is a biotech company that develops and commercializes blood-based biomarker assays that improve the monitoring of cancer therapies and predict patient outcome. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase in serum or cell cultures; and to monitor and predict treatment response in cancer therapy. Biovica International AB was founded in 2009 and is based in Uppsala, Sweden.

Vator Securities acted as financial advisor and Baker McKenzie acted as legal advisor to Biovica in conjunction with the listing on Nasdaq First North. The principal advisor from Baker McKenzie was Joakim Falkner with support from Johanna Flink, Ian Gulam, Stefan Balazs and Per Blom.